Drug class
Non-steroidal mineralocorticoid receptor antagonist; cardiorenal protective agent
Mechanism of action
Selectively antagonises mineralocorticoid receptors, blocking aldosterone- and cortisol-mediated pro-inflammatory and profibrotic signalling in the kidney and cardiovascular system.
General use cases
- Reduction of risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction and hospitalisation for heart failure in adults with chronic kidney disease associated with type 2 diabetes
- Reduction of risk of cardiovascular death, heart failure hospitalisation and urgent heart failure visits in adults with heart failure and left ventricular ejection fraction at least 40% under the 2026 US label; check renal and potassium eligibility criteria
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
